Espen A. Haavardsholm

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update

Josef S Smolen, Robert Landewé, Sytske Anne Bergstra et al. · Annals of the Rheumatic Diseases · 2022 · 1.6K citations · Full text

Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial

Kristin Kaasen Jørgensen, Inge Christoffer Olsen, Guro Løvik Goll et al. · The Lancet · 2017 · 789 citations

Oncology, Clinical Translation, Originator Infliximab +10

EULAR recommendations for the use of imaging of the joints in the clinical management of rheumatoid arthritis

Alexandra N. Colebatch, Christopher J Edwards, Mikkel Østergaard et al. · Annals of the Rheumatic Diseases · 2013 · 647 citations · Full text

High anti-cyclic citrullinated peptide levels and an algorithm of four variables predict radiographic progression in patients with rheumatoid arthritis: results from a 10-year longitudinal study

Silje Watterdal Syversen, Per Ivar Gaarder, Guro Løvik Goll et al. · Annals of the Rheumatic Diseases · 2007 · 311 citations

Magnetic resonance imaging findings in 84 patients with early rheumatoid arthritis: bone marrow oedema predicts erosive progression

Espen A. Haavardsholm, A Schildvold, T.K. Kvien · Annals of the Rheumatic Diseases · 2007 · 291 citations